CJC-1295 with DAC 2mg Injection (Drug Affinity Complex)
Medicine OverView
CJC-1295 with DAC 2mg Injection is a synthetic peptide-based research compound known as a growth hormone releasing hormone (GHRH) analogue. It is designed to stimulate the natural release of growth hormone from the pituitary gland in the body.
This compound is commonly studied in research environments for its potential role in growth hormone regulation, muscle recovery pathways, fat metabolism, and anti-aging related biological processes. The DAC (Drug Affinity Complex) component helps extend the half-life of the peptide, allowing longer activity in the body.
Note: This product is typically used for research purposes only and not approved for general medical use in many regions.
These benefits are based on experimental and research contexts and are not approved medical claims.
CJC-1295 with DAC works by binding to growth hormone releasing hormone (GHRH) receptors in the pituitary gland. This stimulates the release of endogenous growth hormone, which may influence multiple metabolic and regenerative processes.
Side effects may vary depending on dosage, formulation, and individual response in research settings.
It is a research peptide studied for growth hormone release and metabolic effects.
No, it is generally not approved for therapeutic use in humans in many regions.
It stimulates growth hormone release from the pituitary gland.
DAC increases the half-life, allowing longer duration of activity.
Yes, it is used as an injection in research settings.
It is studied in research contexts only and not approved for performance use.
Possible effects include injection site irritation, headache, and water retention in studies.
Safety depends on controlled research environments and professional handling only.
What do you think about this product?